Aytu BioPharma (NASDAQ:AYTU – Get Free Report) was downgraded by analysts at Lake Street Capital from a “buy” rating to a “hold” rating in a research report issued on Tuesday, Marketbeat.com reports. They currently have a $2.70 price target on the stock. Lake Street Capital‘s price target would indicate a potential upside of 1.50% from the company’s previous close.
Several other equities research analysts have also recently issued reports on the stock. Weiss Ratings cut shares of Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Citigroup restated a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Finally, Zacks Research cut shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.60.
Get Our Latest Research Report on AYTU
Aytu BioPharma Price Performance
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.06. Aytu BioPharma had a negative return on equity of 74.74% and a negative net margin of 34.34%. The business had revenue of $14.84 million during the quarter, compared to the consensus estimate of $13.27 million. On average, research analysts expect that Aytu BioPharma will post -0.16 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Stonepine Capital Management LLC bought a new stake in Aytu BioPharma in the second quarter worth $1,962,780. AWM Investment Company Inc. purchased a new stake in Aytu BioPharma during the second quarter valued at $1,332,000. Nantahala Capital Management LLC purchased a new stake in Aytu BioPharma during the second quarter valued at $2,336,646. BlackRock Inc. bought a new position in Aytu BioPharma during the second quarter valued at $49,000. Finally, Crown Advisors Management Inc. bought a new position in Aytu BioPharma during the second quarter valued at $430,000. 33.49% of the stock is owned by hedge funds and other institutional investors.
Trending Headlines about Aytu BioPharma
Here are a few of the latest headlines about AYTU:
- Neutral Sentiment: Maxim Group and Lake Street Capital downgraded AYTU from Buy to Hold; Lake Street’s $2.70 target is in line with the proposed cash offer, leaving the takeover price as a key reference point for investors.
- Negative Sentiment: Coverage of fiscal 2027 first-quarter results said Aytu swung to a loss amid higher costs, which may temper the positive deal news. Aytu BioPharma Swings To Q1 Loss On Higher Costs; Agrees To $56 Mln Buyout By Rosemont
- Negative Sentiment: Several law firms announced investigations into whether the $2.70 offer fairly values Aytu and whether shareholders’ interests were adequately protected. These announcements could add uncertainty around the transaction, though they do not by themselves indicate that the deal will be blocked. Ademi LLP investigates whether buyout fairly values Aytu BioPharma
Aytu BioPharma Company Profile
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
Further Reading
- Five stocks we like better than Aytu BioPharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
